stockrowBeOne Medicines Ltd. - Sponsored ADR
BeOne Medicines Ltd. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.3 billion, up 40.2% from fiscal 2024.
- Revenue
- +33.8%
- EPS
- +143.7%
- Free cash flow
- +33.6%
- Total debt
- +491.3%
Quarter to September 2026, against a year earlier
Follow ONC
Alert me
BeOne Medicines Ltd. - Sponsored ADR (ONC) EBITDA
BeOne Medicines Ltd. - Sponsored ADR's EBITDA for fiscal 2025 was $588.8M, compared with −$396.4M in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.4B. Over the past ten years it has ranged from −$1.7B (fiscal 2022) to $588.8M (fiscal 2025) — the current reading is the highest in ten years. EBITDA has risen for 3 consecutive fiscal years. BeOne Medicines Ltd. - Sponsored ADR ranks 5th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $588.8M | — |
| FY2024 | −$396.4M | — |
| FY2023 | −$1.1B | — |
| FY2022 | −$1.7B | — |
| FY2021 | −$1.4B | — |
| FY2020 | −$1.6B | — |
| FY2019 | −$941.3M | — |
| FY2018 | −$695.4M | — |
| FY2017 | −$93.7M | — |
| FY2016 | −$115.2M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $479.6M | 31.20% |
| Jun 2026 | $365.6M | 25.60% |
| Mar 2026 | $291.0M | 31.68% |
| Dec 2025 | $221.0M | 10.29% |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| ARGX argenex SE compare | $1.7B |
| RPRX Royalty Pharma PLC compare | $1.5B |
| ONC BeOne Medicines Ltd. - Sponsored ADR | $1.4B |
| GMAB Genmab A/S Sponsored ADR compare | $1.2B |
| INCY Incyte Corporation compare | $724.9M |
| INSM Insmed, Inc. compare | −$531.4M |
| ROIV Roivant Sciences Ltd. compare | −$593.3M |
| BNTX BioNTech SE Sponsored ADR compare | −$1.1B |
| RVMD Revolution Medicines, Inc. compare | −$1.6B |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on ONC
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement